Bio-Rad Laboratories has introduced the Vericheck ddPCR™ Empty-Full Capsid Kit, an innovative tool for laboratory managers involved in gene therapy research and production. This new solution enables the accurate measurement of AAV vector quality, helping to optimize gene therapy development and streamline production processes.
The Vericheck ddPCR Kit uses Bio-Rad’s advanced Droplet Digital™ PCR technology to deliver precise and reproducible data on capsid titer, genome titer, and the ratio of full, partial, and empty capsids. This kit provides reliable results from minimal sample input, whether working with purified or crude lysate AAV samples.
Benefits for lab managers:
- Simplifies AAV vector quality control for both early-stage development and routine production
- High-throughput analysis reduces bottlenecks in gene therapy workflows
- Cost-effective solution designed to meet regulatory standards
- Easy to implement with Bio-Rad’s Droplet Digital PCR Systems
- Minimizes the risks of product-related impurities, supporting safer gene therapies
By enhancing the accuracy and efficiency of AAV vector characterization, Bio-Rad’s Vericheck ddPCR Kit ensures that laboratory managers can focus on delivering high-quality, safe gene therapies to market.
This article is an AI generated summary of a published press release provided by Bio-Rad
